Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · IEX Real-Time Price · USD
8.30 -0.29 (-3.38%)
Jan 21, 2022 4:00 PM EST - Market closed
Income Statement (Annual)
Millions USD. Fiscal year is Jan - Dec.
| Year | 2020 | 2019 |
|---|---|---|
| Revenue | 7.66 | 24.65 |
| Revenue Growth (YoY) | -68.94% | - |
| Gross Profit | 7.66 | 24.65 |
| Selling, General & Admin | 9.87 | 7.54 |
| Research & Development | 49.99 | 32.27 |
| Operating Expenses | 59.86 | 39.81 |
| Operating Income | -52.2 | -15.16 |
| Other Expense / Income | -0.23 | -1.07 |
| Pretax Income | -51.97 | -14.1 |
| Net Income | -51.97 | -14.1 |
| Net Income Common | -51.97 | -14.1 |
| Shares Outstanding (Basic) | 11 | 9 |
| Shares Outstanding (Diluted) | 11 | 9 |
| Shares Change | 27.55% | - |
| EPS (Basic) | -4.53 | -1.57 |
| EPS (Diluted) | -4.53 | -1.57 |
| Free Cash Flow Per Share | 6.02 | -2.96 |
| Gross Margin | 100.00% | 100.00% |
| Operating Margin | -681.82% | -61.51% |
| Profit Margin | -678.84% | -57.18% |
| Free Cash Flow Margin | 900.84% | -108.00% |
| EBITDA | -51.25 | -13.45 |
| EBITDA Margin | -669.46% | -54.57% |
| EBIT | -51.97 | -14.1 |
| EBIT Margin | -678.84% | -57.18% |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).